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ABSTRACT
Objective: To characterize the clinical and molecular effect of mutations in the sortilin-related
receptor (SORL1) gene.
Methods:We performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and
late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants.
The phenotypic consequences associated with SORL1 mutations were characterized based on
clinical reviews of medical records. Functional studies were completed to evaluate b-amyloid
(Ab) production and amyloid precursor protein (APP) trafficking associated with SORL1
mutations.
Results: SORL1 alterations were present in 2 EOAD families. In one, a SORL1 T588I change
was identified in 4 individuals with AD, 2 of whom had parkinsonian features. In the second,
an SORL1 T2134 alteration was found in 3 of 4 AD cases, one of whom had postmortem
Lewy bodies. Among LOAD cases, 4 individuals with either SORL1 A528T or T947M
alterations had parkinsonian features. Functionally, the variants weaken the interaction of
the SORL1 protein with full-length APP, altering levels of Ab and interfering with APP
trafficking.
Conclusions: The findings from this study support an important role for SORL1 mutations in AD
pathogenesis by way of altering Ab levels and interfering with APP trafficking. In addition, the
presence of parkinsonian features among select individuals with AD and SORL1mutations merits
further investigation. Neurol Genet 2016;2:e116; doi: 10.1212/NXG.0000000000000116
GLOSSARY
AAO 5 age at onset; Ab 5 b-amyloid; AD 5 Alzheimer disease; APP 5 amyloid precursor protein; APPsb 5 APP soluble
b-secretase; APPsw 5 Swedish APP mutant; EOAD 5 early-onset Alzheimer disease; ER 5 endoplasmic reticulum;
FL-APP 5 full-length APP; HIHG 5 John P. Hussman Institute for Human Genomics; LOAD 5 late-onset Alzheimer disease;
PD 5 Parkinson disease; SORL1 5 sortilin-related receptor; WES 5 whole-exome sequencing.
Alzheimer disease (AD) is the leading cause of dementia in the elderly.1 Multiple genes have
been implicated in risk for both late-onset Alzheimer disease (LOAD; onset .65 years of age)
and early-onset Alzheimer disease (EOAD; onset ,65 years of age)2 including the sortilin-
related receptor (SORL1) gene. Located on chromosome 11q23.2-q24.2, SORL1 influences the
differential sorting of the amyloid precursor protein (APP) and regulation of b-amyloid (Ab)
production, making it biologically plausible for AD risk.3–9
Compelling evidence for the involvement of SORL1 in AD comes from a large meta-analysis
of.30,000 individuals, which confirmed that variants in SORL1 are associated with AD risk.10
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Furthermore, whole-exome sequencing (WES)
has identified potentially damaging SORL1
mutations in patients with both EOAD and
LOAD.11,12 Of note, a WES study of a large
EOAD cohort found a greater frequency of
predicted damaging missense SORL1 variants
in cases vs controls, with this effect enriched
among cases with a positive family history.13
Clearly, rare coding variants in SORL1 are tied
to risk for EOAD and LOAD. Finally, while
SORL1 mutations have been reported in mul-
tiple patients with AD, there has been little
investigation of clinical phenotypes beyond
dementia and age at onset (AAO) among these
individuals.
For this study, we examined well-characterized
EOAD families using WES to discover AD risk
genes. Our efforts focused on clinical character-
ization of individuals with SORL1 alterations
and investigation of the functional effect of the
identified SORL1 alterations in a series of gene
overexpression experiments.
METHODS Standard protocol approvals, registrations,
and patient consents. All participants ascertained for this study
gave written informed consent prior to their inclusion. If an indi-
vidual was not competent to give consent, the immediate next of
kin or a legal representative provided written consent on their
behalf. All participants were ascertained using a protocol that
was approved by the appropriate Institutional Review Board.
Oversight of this study falls under the University of Miami
Institutional Review Board #20070307.
Sources of participants. EOAD families were ascertained as
part of a larger study on AD genetics whose participants were
enrolled under protocols previously described.14,15 Individuals
were ascertained for this study after they provided informed con-
sent at the John P. Hussman Institute for Human Genomics
(HIHG) at the University of Miami Miller School of Medicine
(Miami, FL). The majority of these families were self-reported
non-Hispanic whites (N 5 47); the remaining families were self-
reported African Americans (N 5 3). Clinical data from
cognitively impaired individuals, including any that changed
affection status, were evaluated by the HIHG AD clinical staff
which includes a psychiatrist, neurologist, and neuropsychologist.
Familial EOAD cases were defined as AAO ,65 years of age. As
reported in previous studies, AAO was defined as the age at which
an individual or family historian reported onset of significant
cognitive problems that interfered with normal activity, or the
AAO of problems as documented in the medical record.15 All
affected individuals met the internationally recognized standard
NINCDS-ADRDA criteria.16,17 The cognitive status of
participants was measured using either the Mini-Mental State
Examination18 or the Modified Mini-Mental State.19
Patients with LOAD (N 5 151) were part of a study investi-
gating coding mutations in SORL1 in AD.11 These participants
were drawn from a larger study of AD genetics restricted to
Caribbean Hispanics. All affected individuals were of Caribbean
Hispanic ancestry. All participants were assessed using standard
clinical examinations and cognitive testing as described elsewhere.20
For this study, we reviewed the clinical records of participants who
had SORL1 mutations to assess for possible features of Parkinson
disease (PD) or more broadly, parkinsonism.
WES and variant calling. All samples were prepared using
DNA extracted from the blood. Genomic DNA was then sheared
and processed using the SureSelect Human All Exon 50 Mb v4
capture kit (Agilent Technologies, Santa Clara, CA) according
to the manufacturer’s protocol at the HIHG Center for Genome
Technology. After capture, the DNA was tested for uniform
enrichment of targets via quantitative PCR. Sequencing was then
performed on the Illumina HiSeq2000 at 23 150 bp paired-end
cycles at 40–503 on target depth. Exomes were sequenced to
sufficient depth to achieve a minimum threshold of 80% of
coding sequence covered with at least 15 reads, based on UCSC
hg19 “known gene” transcripts. The mean depth of coverage
across SORL1 was 68.
Sequencing data from the Illumina HiSeq2000 were pro-
cessed using an established semiautomated pipeline. Initial
image files were processed using the Firecrest module (Illumina,
San Diego, CA) to determine cluster intensities and noise. After
initial quality control, BWA-ELAND and CASAVA v1.9
were used for realignment to the human genome version
hg19. Results from BWA and CASAVA are then fed into addi-
tional software packages (CLC Genomics Workbench and Ge-
nomeStudio) for secondary analysis, visualization of the called
variants, and browsing of consensus reads.21,22 Genotype calling
was performed with GATK Unified Genotyper. Variants were
then normalized using BCFTools.23 Single nucleotide polymor-
phisms with read depth ,6, variant quality score log odds ratio
,0, and Phred-scaled likelihood score ,100 were removed
from further analysis. Variants were filtered to identify altera-
tions that were likely to be damaging (missense, splicing, stop-
gain, stop-loss, and insertion/deletions) in Gencode v19, NCBI
RefSeq, or Ensembl gene annotations.24,25 Variants were
screened to determine whether they occurred in a known or
suspected EOAD gene (APP, GRN, MAPT, PSEN1, PSEN2,
SORL1, and TREM2). Minor allele frequencies were obtained
from the Exome Aggregation Consortium.26
Cloning of SORL1 variants. Site-directed mutagenesis was
used to generate the SORL1 T588I and SORL1 T2134IMmuta-
tion constructs using human SORL1-MYC pcDNA3.1 as
a backbone according to the manufacturer’s instructions as
previously published.3,11,27–30 Sequencing was used to verify
mutant constructs. Cell culture and transfection followed
previously described standard protocols.3,11,27–30
Ab, Western blot, and co-immunoprecipitation assays.
Ab assays were measured by sandwich ELISA assay in culture
medium from stably transfected HEK293 cells expressing
the Swedish APP mutant (APPsw) and either wild-type SORL1
or mutant SORL1 as previously described.3,11,27–30 Cell surface
biotinylation was performed using 1 mg/mL Sulfo-NHS-LC-
Biotin (Sigma-Aldrich, St. Louis, MO) for 20 minutes at 4°C
to prevent internalization. Cells were then washed and lysed, and
biotinylated proteins were precipitated with NeutrAvidin beads
(Thermo Fisher Scientific, Waltham, MA). Western blot band
intensities were measured with ImageJ software and samples
normalized to the wild-type control. Co-immunoprecipitation
was performed after cell lysis in 1% CHAPSO buffer,3 using G
Plus beads with 2 mg mouse monoclonal anti-c-MYC antibody
for the immunoprecipitation of SORL1-myc, immunoblotted
with anti-C-terminal APP antibody (Ab365), and anti-C-
terminal SORL1 (S9200). Western blot band intensities were
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measured with ImageJ software. Full-length (FL) APP
coprecipitated with c-MYC antibody was quantified and
normalized to the amount of immunoprecipated SORL1 as
previously described.3,11,27–30
Statistical analyses. Statistical analyses were performed using
Graphpad statistical software (graphpad.com/guides/prism/5/
user-guide/prism5help.html?using_tour_overview.htm;
GraphPad Prism 5). Analysis of variance and t tests were used to
analyze statistical difference, followed by Bonferroni correction
(*p , 0.05; **p , 0.01; and ***p , 0.001).
RESULTS SORL1 variants in EOAD families. WES
identified 10 individuals with SORL1 mutations in
2 unrelated EOAD families (table 1, figure 1). Neu-
ropathology results were available for 1 affected indi-
vidual. The first family, number 191, has 6
individuals with the predicted damaging SORL1
T588I mutation (rs752726649; C.T); all 4 affected
individuals for whom DNA was available were found
to carry this variant. These 4 affected individuals had
AAOs that ranged from 59 to 82 years. While the
progressive cognitive decline of each individual was
consistent with dementia, individuals 104 and 111
had also parkinsonian features. Individual 104 began
to show cognitive impairment at age 82. On exami-
nation, he demonstrated tremor at rest, hypophonia,
micrographia, masked facial expression, smaller steps
on gait, and overall bradykinesia. Chart review indi-
cated that these symptoms were levodopa/carbidopa
responsive. Imaging revealed white matter changes
and moderate cerebral atrophy, and EEG was remark-
able for a loss of alpha waves. Individual 111 had the
earliest AAO in the family 191 at age 59, with dimin-
ished memory function in all domains, clinically
judged to most likely represent EOAD. When seen
by research staff at age 70, the individual was noted to
exhibit parkinsonian features. This presentation was
confounded by several years of treatment with halo-
peridol, a typical antipsychotic agent that can cause
parkinsonian side effects. Two unaffected individuals
in family 191 also carried the SORL1 T588I
mutation. These individuals were last examined at
ages 81 and 84 years, respectively. Individuals 116
and 9004 demonstrated a normal cognitive and
physical examination.
The second family, number 1240 (table 1 and
figure 1), contains 3 affected individuals with the
SORL1 T2134M mutation (rs142884576; C.T).
These 3 affected individuals had AAOs that ranged
from 55 to 84 years. While the clinical examinations
revealed no motor abnormalities, there was autopsy
evidence for Lewy bodies in individual 1, with the
earliest AAO in the family at 55 years. Neuropatho-
logic diagnosis of individual 1 was indicative of Braak
& Braak stage IV tangles and limbic Lewy bodies. In
addition, 1 individual (119) demonstrated progressive
cognitive decline consistent with AD without the
T2134M SORL1 mutation. This individual had an
AAO of 76 years. Finally, there was 1 unaffected
individual (113) with this T2134M SORL1 muta-
tion who was last examined at 79 years of age.
Parkinsonian features in patients with LOAD with
SORL1 variants. Given the clinical results from these
2 EOAD families, we examined in greater depth the
clinical status of previously reported patients with
SORL1 changes.11 Review of clinical history and
physical examination data identified 4 additional
AD individuals, all with LOAD (no neuropathology
results were available), and who had evidence of
Table 1 Clinical features in early-onset AD families with SORL1 variants
Family-individual Sex
Affection
status
Additional
features AAO/AAE
Base pair position
(hg38 assembly) Nucleotide Amino acid dbSNP numbera APOE status
191-1 M Dementia AD — 73 121543625 C.T T588I rs752726649 3/4
191-104 F Dementia AD Parkinsonian 82 121543625 C.T T588I rs752726649 3/4
191-111 M Dementia AD Parkinsonian 59 121543625 C.T T588I rs752726649 3/4
191-114 M — — 90 — — — — 3/3
191-116 M — — 84 121543625 C.T T588I rs752726649 3/3
191-9003 M Dementia AD — 81 121543625 C.T T588I rs752726649 3/3
191-9004 M — — 81 121543625 C.T T588I rs752726649 3/3
1240-1 M Dementia AD DLB, no PD 55 121627591 C.T T2134M rs142884576 3/3
1240-101 F Dementia AD — 80 121627591 C.T T2134M rs142884576 3/3
1240-111 F Dementia AD — 84 121627591 C.T T2134M rs142884576 3/3
1240-113 M — — 79 121627591 C.T T2134M rs142884576 3/3
1240-119 F Dementia AD — 76 — — — — 3/4
Abbreviations: AAE5 age at examination; AAO5 age at onset; AD5 Alzheimer disease; DLB5 dementia with Lewy bodies; PD5 Parkinson disease; SNP5
single nucleotide polymorphism.
aMinor allele frequencies (MAF): rs752726649 global MAF 5 8.2 3 1026; rs142884576 global MAF 5 2.2 3 1024.
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parkinsonian features (table 2). The SORL1 muta-
tions in these 4 individuals were distinct from those
identified in the first 2 families. Specifically, 3 indi-
viduals which we previously reported carry a common
variant at A528T (rs2298813A.G). Clinically, these
individuals were diagnosed with both AD and PD
and had ages of AD onset ranging from 78 to 84
years. The fourth individual had a different previously
reported missense T947M variant (rs143571823,
C.T). This individual had a clinical diagnosis of
AD and parkinsonism with an age of AD onset at
90 years.
SORL1 variants alter Ab levels and APP trafficking.
Next, we examined the functional consequences of
the SORL1 T588I and T2134M alterations identi-
fied in the EOAD families; the variants identified
in the LOAD individuals (A528T and T947M) were
previously assessed and reported.11 To determine the
effects on Ab production by these SORL1 variants,
Ab42 and Ab40 levels were measured in conditioned
media collected from cultured HEK293 cells express-
ing equivalent levels of wild-type SORL1 protein,
SORL1 T588I, or SORL1 T2134M. Both mutants
increased Ab42 secretion compared with the control
(T588I: 113% 6 1.6% and T2134M: 117% 6
5.1%, p , 0.05, figure 2A). Overexpression of
SORL1 T2134M also increased Ab40 secretion
(167% 6 9.9%, p , 0.001, figure 2B). While the
Table 2 Clinical features in late-onset AD individuals with SORL1 variants
Family-individual Sex Affection status Additional features AAO Base pair position (hg38 assembly) Nucleotide Amino acid dbSNP numbera APOE status
216-9 M Dementia AD Parkinsonian 78 121522975 A.G A528T rs2298813 2/4
920-10 F Dementia AD Parkinsonian 83 121522975 A.G A528T rs2298813 3/4
1280-18 F Dementia AD Parkinsonian 90 121558767 C.T T947M rs143571823 3/4
1731-1 M Dementia AD Parkinsonian 84 121522975 A.G A528T rs2298813 3/3
Abbreviations: AAO 5 age at onset; AD 5 Alzheimer disease; SNP 5 single nucleotide polymorphism.
aMinor allele frequencies (MAF): rs2298813 MAF 5 0.072; rs143571823 MAF 5 0.0013.
Figure 1 Pedigrees of the early-onset Alzheimer disease families and SORL1 protein diagram
(A and B) Pedigrees of the early-onset Alzheimer disease (EOAD) families and SORL1 protein diagram. Affected individuals are solid black while those pre-
senting with parkinsonian features are patterned. Below each individual number is either the age at onset (AAO, for affected individuals) or the age at last
examination (AAE, for unaffected individuals). For family 191, the SORL1 variant is present in all affected individuals examined. In family 1240, the variant
occurs in 3 of 4 cases evaluated. (C) Diagram of SORL1 protein (2214 total amino acids) indicating the location of principal domains and the variants
identified in the EOAD families (T588I and T2134M) and the late-onset Alzheimer disease individuals (A528T and T947M). AD5 Alzheimer disease; VPS10
5 vesicular protein sorting 10 domain; CR 5 complement type repeat domains; EGF 5 epidermal growth factor; FNIII 5 fibronectin type III repeats; TM 5
transmembrane region; DLB 5 dementia with Lewy bodies; SORL1 5 sortilin-related receptor.
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SORL1 T588I alteration trended toward an increase
of Ab40 secretion in cells, it did not reach statistical
significance (131% 6 17.6%, figure 2B).
SORL1 has been proposed to modulate the post-
translational biology of APP at several intracellular sites
including during transport out of the Golgi and during
re-entry and recycling from the cell surface. To exam-
ine further the effect of these SORL1 mutants on
APP trafficking, we measured APP soluble b-secretase
(APPsb) secretion in a conditioned medium.31 Both
mutations caused an increase in APPsb secretion com-
pared with the wild-type SORL1 (T588I: 132% 6
6.3%, p , 0.05; T2134M: 140% 6 9.4%, p ,
0.05, figure 2C). Both mutations also increased pro-
duction of the soluble a-secretase cleavage product
compared with control cells (T588I: 207% 6
15.8%, p , 0.01; T2134M: 223% 6 29.6%, p ,
0.05, figure 2D). These observations suggest that in
the presence of these SORL1 mutants, APP is neither
retained efficiently in the Golgi nor effectively retrieved
from the cell surface into recycling pathways. This
could result in additional APP lingering at the cell
surface. This hypothesis was supported by surface bio-
tinylation experiments which revealed that both
SORL1 mutants increased the amount of surface
APP compared with the control (T588I: 143% 6
13.1%, p , 0.05; T2134M: 138% 6 7.5%, p ,
0.05, figure e-1 at Neurology.org/ng).
SORL1 variants decrease APP binding. To understand
the mechanism by which these SORL1 mutants
might alter APP trafficking at the cell surface, we
next measured levels of SORL1 protein at the cell
surface. The T588I variant showed essentially nor-
mal levels of SORL1 both at the cell surface and in
total cell lysates (;87% 6 13.1% of control value,
figure e-1). However, while the T2134M mutant
showed normal levels of total cellular SORL, there
were decreased amounts of surface SORL1 (;25%,
p , 0.05, figure e-1B).
Figure 2 SORL1 mutants’ overexpression increases b-amyloid secretion
(A–C) Secreted b-amyloid 40 (Ab40), Ab42, and amyloid precursor protein soluble b-secretase (APPsb) were measured from culture medium in stable
HEK293 cells expressing the APP Swedish mutant (HEKsw) together with either wild-type SORL1 or mutant SORL1. Error bars represent standard error of
the mean (SEM). ***p , 0.001, *p , 0.05, ns, not significant, n 5 3 independent replications. (D) Western blot was performed to detect APP soluble
a-secretase (APPsa) from cultured media. Bar graphs were normalized to control. **p , 0.01, n 5 3 independent replications, and error bars represent the
SEM. Ab 5 b-amyloid; FL-APP 5 full-length APP; SORL1 5 sortilin-related receptor.
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Previous work by us and others have demonstrated
that SORL1 directly binds APP and regulates its sort-
ing into secretory, endocytic, or recycling path-
ways.3,4,11,27,32–38 To assess whether the SORL1
T588I and T2134M mutations might alter the bind-
ing affinity of SORL1 to APP, we immunoprecipi-
tated SORL1 from whole cell lysates using an
anti-myc antibody directed to the myc epitope on
the exogenous SORL1 protein. This strategy circum-
vents possible risk that the SORL1 mutants might
alter binding affinity of anti-SORL1 antibodies, or
that endogenous SORL1 might be pulled down in
addition, to overexpressed SORL1 in the mutant
APPsw cell lines. We then measured the amount of
FL-APP that co-immunoprecipitated with the myc-
tagged SORL1 proteins and expressed the binding as
a normalized ratio of the abundance of coprecipitated
FL-APP relative to the abundance of immunopreci-
pitated SORL1. Both mutations caused reductions in
APP binding (T588I: ;77.1% 6 5.8%, p , 0.05;
T2134M: ;61.5% 6 8.3%, p , 0.05, figure 3).
DISCUSSION In this study, we identified SORL1
alterations in EOAD families thus confirming previ-
ously reported studies showing a role for SORL1 in
risk for EOAD. Furthermore, we presented func-
tional evidence that these SORL1 alterations are
pathogenic.
Evidence for functional consequences of SORL1
mutations is scant. However, the evidence shown
here suggests that the variants identified in the
EOAD families, SORL1 T588I and T2134, weaken
the interaction of SORL1 with FL-APP. This can
culminate in excessive APP accumulating at the cell
surface either due to failure of the mutant SORL1 to
slow trafficking of APP to the cell surface39 or failure
of mutant SORL1 to retrieve FL-APP into the
retromer-recycling endosome pathway.3,4,11,27,32–38
Our result agrees with prior work which suggests that
some SORL1mutants cause reduced trafficking of the
mutant SORL1 protein from the endoplasmic retic-
ulum (ER)/Golgi network to the cell surface.11 The
resulting misdirection of more APP into the late en-
dosome pathway exposes the APP to b-secretase and
g-secretase cleavage, with the consequent increase in
Ab production, especially Ab42. Intriguingly, but
consistent with prior work, our data suggest that
the molecular mechanisms underlying this common
overall effect differ between the 2 variants. Thus, the
T2134M mutant, which is located close to the trans-
membrane domain (figure 1), appears to disrupt traf-
ficking of SORL1 to the cell surface, presumably due
to its removal from the ER-Golgi secretory pathway
by the ER quality control systems which remove mis-
folded proteins. In contrast, the T588I mutant sur-
vives the ER quality control mechanisms, but appears
to be less efficient than wild-type SORL1 in binding
to APP. The molecular mechanism for the reduced
binding of T588I is unclear, but may relate to subtle
changes in the fold of the extracellular domain of
SORL1 such that putative APP-binding sites in
VPS10 and/or in complement type repeat do-
mains.39,40 Crucially, while they may have different
underlying molecular mechanisms, the net effect of
both mutations is the same.
A secondary finding in our study was the observa-
tion of additional clinical features beyond AD among
select individuals with SORL1 alterations. These clin-
ical findings, based on extensive clinical reviews,
included clinical Parkinson-related features and
neuropathology-proven Lewy bodies without clini-
cal parkinsonism. While these findings point to
Figure 3 Both SORL1 mutants have a reduced binding affinity to APP
SORL1 was immunoprecipitated from cell lysates with a c-MYC antibody, and the amount of coprecipitated full-length amyloid precursor protein (FL-APP)
was measured by densitometry of the anti-APP immunoreactive bands on the Western blot of the SORL1 immunoprecipitation products. *p , 0.05, **p ,
0.01, n 5 3 replications, and error bars represent the SEM. IgG 5 immunoglobulin G; IP 5 immunoprecipitated; SORL1 5 sortilin-related receptor.
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a potential association between SORL1 alterations
and a broader spectrum of neurodegenerative disor-
ders, it is important to note that these clinical features
were not present in all individuals with SORL1 alter-
ations and may simply represent features of coinci-
dental sporadic PD.
The results from this study demonstrate that
select SORL1 variants present in EOAD and LOAD
alter Ab levels and interfere with APP trafficking. In
addition, we observed parkinsonian features among
some EOAD/LOAD individuals with SORL1 alter-
ations. These clinical findings should be viewed cau-
tiously but suggest the need for exploration of the
additional phenotype consequences of SORL1 alter-
ations beyond dementia.
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